Omigapil: Completed Phase I enrollment

Santhera completed enrollment of 20 ambulatory and non-ambulatory patients ages 5-16 in the open-label, dose-escalation, U.S. Phase I CALLISTO trial evaluating 0.02, 0.08 and 0.2 mg/kg/day oral omigap...